The company's immunotherapies harness immune response mechanisms and target immune receptors to amplify the immune response, increasing patient survival and reducing side effects. Adzebiotech's self-amplifying oncolytic viruses deliver immune-stimulatory and immune evasion blocking proteins to tumors, killing cancer cells directly and exposing cancer antigens to the immune system. Founded in 2019, the company is based in Coral Gables, Florida, and holds exclusive licenses to oncolytic immunotherapies developed in the lab of Dr. Michael Barry of Mayo Clinic.